Nouscom AG
Industry
- Biotechnology
- Large Molecule
- Gene Therapy, Cell Therapy
- Pharmaceuticals
- Drug Delivery
- Macromolecule
- Vaccines
- Drug Delivery
Latest on Nouscom AG
Two new venture capital funds based outside of the US together offer $365m for life science start-ups, including Amplitude Ventures’ second fund and XGEN Venture’s inaugural fund. Montreal-based Ampli
Marina Udier faces a challenging task as CEO of NousCom AG , a Basel, Switzerland-based biotech developing neoantigen-based vaccines. While the concept has been around for years without significant c
Capstan Therapeutics Inc. and Engrail Therapeutics are among the latest companies to raise venture capital mega-rounds of $100m or more as the deluge of large private financings early in 2024 coinc
The mood around the BIO-Europe conference in Munich in November was positive as people in the biotech world, or at least 5,500 of them, gathered to talk shop at over 30,000 partnering meetings. Howeve